1. Home
  2. TENX vs NSRX Comparison

TENX vs NSRX Comparison

Compare TENX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$12.82

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$5.60

Market Cap

52.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
NSRX
Founded
1967
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
52.5M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
TENX
NSRX
Price
$12.82
$5.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$22.50
$20.50
AVG Volume (30 Days)
294.1K
4.6K
Earning Date
03-24-2026
03-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$4.90
52 Week High
$18.38
$9.99

Technical Indicators

Market Signals
Indicator
TENX
NSRX
Relative Strength Index (RSI) 46.69 41.46
Support Level $12.53 $4.90
Resistance Level $14.08 $6.30
Average True Range (ATR) 0.95 0.41
MACD -0.23 -0.04
Stochastic Oscillator 17.74 40.49

Price Performance

Historical Comparison
TENX
NSRX

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: